Authors: Keerthi Kumar
Abstract: The convergence of Artificial Intelligence (AI) and nanomedicine has sparked a transformative wave in the biomedical and pharmaceutical industries, opening new pathways for disease diagnosis, treatment, and drug delivery at the nanoscale. As AI technologies enhance the design, functionality, and application of nanomaterials, nanomedicine ventures have become highly attractive to investors seeking long-term value and breakthrough innovations. This paper presents a comprehensive analysis of investment strategies in AI-driven nanomedicine ventures, focusing on the unique technological, financial, and regulatory dynamics of this rapidly growing domain. From venture capital and private equity to public funding and strategic partnerships, the investment landscape surrounding AI-nanomedicine is evolving, driven by innovation potential, patient demand, and the promise of market disruption. By examining investment trends, risk management techniques, key success factors, and emerging market opportunities, this paper offers a strategic framework for stakeholders aiming to capitalize on this cutting-edge intersection of technology and healthcare.
DOI: http://doi.org/
